PCMO L01—Setting Specifications for Biological Investigational Medicinal Products

References

1. 1.↵
   ICH Guidance for Industry Q8(R2): Pharmaceutical Development.
2. 2.↵
   ICH Guidance for Industry Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities).
3. 3.↵
   ICH Guidance for Industry Q9: Quality Risk Management.
4. 4.↵
   ICH Guidance for Industry Q10: Pharmaceutical Quality System.
5. 5.↵
   ICH Guidance for Industry Q6B: Specifications: Test Procedures and Acceptance Criteria.
6. 6.↵
   A-Mab: A Case Study in Bioprocess Development, CASSS- ISPE.
7. 7.↵
   EBE: Concept Paper, Considerations in Setting Specifications, 28 March 2013.
8. 8.↵
   1. Allen P. V.

   Determination of release limits: ageneral methodology. Pharm. Res. 1991, 8(9), 1210–1213.

   OpenUrlPubMed
9. 9.↵
   EudraLex. The Rules Governing Medicinal Products in the European Union, Volume 4. EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Annex 13.
10. 10.↵
    1. Rathore A. S.,
    2. Mhatre R.

    1. Schenerman M. A.,
    2. Axley M. J.,
    3. Oliver C. N.,
    4. Ram K.,
    5. Wasserman G. F.

    Using a Risk Assessment Process to Determine Criticality of Product Quality Attributes. In Quality by Design for Biopharmaceuticals: Perspectives and Case Studies; Rathore A. S., Mhatre R., Eds.; Wiley Interscience: Hoboken, NJ, 2009;pp 53–84.
11. 11.↵
    1. Krause S.

    , WCBP Meeting, 30 Jan 2013, Washington, DC.
12. 12.↵
    1. Krause S.

    , CaSSS CMC Strategy Forum, 27 Jan 2014, Washington, DC.
13. 13.↵
    PDA Technical Report 57. Analytical Method Validation and Transfer for Biotechnology Products, 2012.
14. 14.↵
    1. Krause S

    . Validation of Analytical Methods for Biopharmaceuticals: A Guide to Risk-Based Validation and Implementation Strategies; PDA/DHI Publication: Bethesda, MD, 2007.
15. 15.↵
    EMA, Report of the Expert Workshop on Setting Specifications for Biotech Products, London, 09 September 2011.
16. 16.↵
    Ph. Eur. Monograph on Monoclonal Antibodies for Human Use, 2013.
17. 17.↵
    1. Griffiths E

    . WHO expert committee on biological standardization—highlights of the meeting of October 1996. Biologicals 1997, 25(3), 359–362.

    OpenUrl
18. 18.↵
    USP <61> Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests.
19. 19.↵
    USP <85> Bacterial Endotoxins Test.
20. 20.↵
    EP 2.9.19 Particulate Contamination: Sub-visible Particles and USP <788> Particulate Matter in Injections.
21. 21.↵
    USP <1> Injections.
22. 22.↵
    EP 2.9.17. Test for Extractable Volume of Parenteral Preparations.
23. 23.↵
    USP <71> Sterility Tests.
24. 24.↵
    1. Mire-Sluis A.,
    2. Frazier M.,
    3. May K.,
    4. Lacana E.,
    5. Green N.,
    6. Dye E.,
    7. Krause S.,
    8. Shacter E.,
    9. Reischl I.,
    10. Deshpande R,
    11. Kutza J.

    Accelerated product development: leveraging industry and regulator knowledge to bring products to patients quickly. Bioprocess Intl., 11 December 2014.